ETHICS & HEALTHCARE STRATEGY
Why the future of Indian healthcare depends on trust between industry and patient organisations
By Ram Khandelwal | Founder & CEO, Heart Health India Foundation
In short: Ethical patient engagement is not about refusing industry funding. It is about designing partnerships in which the independence of patient organisations survives contact with money. India’s UCPMP 2024 regulates how pharmaceutical companies engage doctors, but says almost nothing about how they should engage patient organisations. This article proposes a way to fill that silence — the TRUST framework, five governance questions, and an Indian Charter for Ethical Patient Engagement.
Key Takeaways: Ethical Patient Engagement at a Glance
- Ethics is not the absence of funding — it is the presence of independence. Funding is ethically neutral; dependency is not.
- UCPMP 2024 is silent on patient organisations. That silence is an invitation to raise the standard voluntarily, not a loophole to exploit.
- The governance test: would the organisation publish the same report even if its sponsor disagreed with the conclusions?
- Six failure patterns recur in industry–patient organisation partnerships, from disguised marketing to single-sponsor capture.
- The TRUST framework for ethical patient engagement — Transparency, Respect for Independence, Unmet Need First, Scientific Integrity, Trust Through Governance.
- India can lead. A co-created Indian Charter for Ethical Patient Engagement could set the benchmark for the Global South.
Why Trust Is the Foundation of Indian Healthcare
On 16 December 2019, at the age of thirty-three, I became a heart attack survivor. Until that morning, healthcare had been something I encountered occasionally—a prescription here, a consultation there, an inconvenience to be scheduled around real life. By nightfall it had become the system that would determine how I lived, worked, thought, and planned everything that came next. Like millions of patients before me, I had assumed that healthcare revolved around medicines, hospitals, and doctors. I left the hospital understanding something quite different.
Healthcare is built on relationships. The relationship between a patient and a physician. Between science and society. Between innovation and access. Between clinical evidence and lived experience. And underneath all of them sits a single, fragile foundation: trust. Patients trust physicians to prescribe on clinical need alone. Society trusts regulators to keep unsafe medicines off the shelf. Governments trust evidence to shape policy. Increasingly, one more relationship is becoming just as consequential—the one between industry and patient organisations. And it is the relationship we understand least.
Ethics is not the absence of funding. Ethics is the presence of independence.
That single idea is the argument of this article. The debate about pharmaceutical companies and patient groups tends to collapse into two exhausted positions. One says industry money inevitably corrupts the patient voice. The other says patient organisations cannot survive without it. Both are half-right, and both miss the point. The question was never whether to collaborate. Healthcare has become far too complex for any single stakeholder to fix alone. The question is how to collaborate in a way that strengthens public trust rather than quietly eroding it. That is what ethical patient engagement means in practice.
UCPMP 2024 and Patient Organisations: The Silence in the Code
India deserves real credit for the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024. It reinforces principles that should anchor every responsible healthcare interaction: promotional claims must rest on up-to-date evidence, scientific information must be balanced and verifiable, communication must not mislead directly or by implication, and companies remain accountable for the conduct of everyone acting on their behalf. The Code sets clear expectations for continuing medical education, research support, gifts, hospitality, brand reminders, and a genuine complaints-and-appeals mechanism. These are meaningful advances.
But read the Code closely and one thing becomes unmistakable. It is built almost entirely around the pharmaceutical company’s relationship with the healthcare professional. Doctors, medical representatives, prescribers, CME speakers—these are named on nearly every page. Patient organisations are essentially absent. The Code tells a company precisely how it may and may not engage a cardiologist. It says almost nothing about how it should engage the community of cardiac patients that cardiologist treats.
It would be easy to read that silence as a loophole—an unregulated space to be exploited. That reading would be a mistake. The spirit of the UCPMP is far more important than the letter of what it happens not to prohibit. Its core commitments—balanced information, transparency, scientific integrity, accountability, and auditability—do not stop at the clinic door. They extend, logically and morally, to every partnership a company forms with the people who live with the diseases its products treat. The silence in the Code is not permission. It is an invitation—and a responsibility.
The Patient Advocacy Funding Paradox Nobody Names
Consider how every stakeholder in healthcare is financed. Hospitals generate revenue. Universities win grants. Researchers secure funding. Clinicians earn professional fees. Governments allocate public budgets. Pharmaceutical and medical-technology companies invest in R&D while running sustainable commercial enterprises. Every one of these actors operates inside an established economic model. Patient organisations, almost alone, are expected to perform an expanding set of sophisticated functions on the thinnest of institutional foundations.
And the functions are not small. Patient organisations educate patients and caregivers, run helplines, produce multilingual materials, support caregivers, contribute to guideline development, participate in policy and regulatory consultations, feed into health technology assessment, generate patient-reported outcomes, mobilise communities during public-health emergencies, and advocate for equitable access. Increasingly they are asked to do all of this on volunteer effort and short, project-tied grants.
Healthcare invests the least in the very institutions it now most depends on for the patient voice.
This is the patient-advocacy paradox. The system increasingly recognises that engagement improves early diagnosis, adherence, trial design, and policy—yet it starves the organisations expected to deliver that engagement. The result is predictable and, ironically, dangerous. Chronic under-funding forces dependence on short-term cycles that make governance, professionalisation, and long-term planning almost impossible. And that dependence is precisely what breeds real and perceived conflicts of interest. The problem, in other words, is rarely funding itself. Funding is ethically neutral. The problem is dependency.
Pharma Funding and Patient Organisations: The Line Between Support and Influence
If funding is neutral, where is the line? It sits at a single, testable point: the moment financial support begins to shape what an organisation is willing—or unwilling—to say. A company underwriting evidence-based patient education is not acting unethically. Nor is one funding leadership development, disease registries, patient-navigation services, or health-literacy programmes in regional languages. What crosses the line is when money starts to influence scientific content, advocacy priorities, or public positions.
I use a simple governance test, and I recommend it to every board I advise. Would this organisation publish exactly the same report, advocate exactly the same policy position, and communicate exactly the same evidence even if its sponsor strongly disagreed with the conclusions? If the answer is yes, independence is intact and the partnership is collaboration. If the answer is no—if the sponsor’s disapproval would soften a finding, delay a statement, or bury a risk—then the relationship has already moved from collaboration into influence, whatever the paperwork says.
The goal, then, is not to eliminate partnerships. It is to design them so that independence survives contact with money. That is a governance problem, not a moral one—and governance problems have solutions.
Where Industry–Patient Organisation Partnerships Go Wrong: Six Warning Signs
In my experience, almost no collaboration begins with cynical intent. Most start with a sincere wish to help patients. The trouble emerges later, when governance fails to grow at the same pace as ambition. A handful of failure patterns recur across markets, and they are worth naming plainly, because you cannot guard against what you refuse to describe.
- 1. Awareness that is really marketing. A “disease awareness” campaign that quietly steers toward a single therapeutic option is not education; it is promotion wearing education’s clothes.
- 2. Endorsement mistaken for engagement. A patient organisation exists to represent patients, not to validate a commercial strategy. The moment it recommends brands or amplifies promotional messaging, public confidence weakens.
- 3. Ghost-written patient stories. When a company drafts the narrative and the patient merely signs it, lived experience becomes a marketing asset rather than evidence.
- 4. Single-sponsor capture. Where one funder dominates, there is rarely any explicit pressure to change positions. The pressure is implicit. Over time uncomfortable questions go unasked and inconvenient positions grow quieter. Independence is seldom lost overnight; it erodes through silence.
- 5. Tokenism and conference tourism. Inviting one representative to speak, or to review a document days before publication, is not partnership. Nor is selecting patient voices for their visibility rather than their lived experience.
- 6. Performative collaboration. Healthcare has grown comfortable celebrating the number of MoUs signed, campaigns launched, and events held—while paying far less attention to whether any of it improved diagnosis, adherence, or quality of life. The sector has never lacked activity. It lacks measurable impact.
Every one of these practices sits in tension with the UCPMP’s own principles—balanced information, no misleading by implication, no disguising the real nature of promotional material. That is the point. The Code may not mention patient organisations, but its logic already condemns the worst of what goes wrong between them and industry.
What Global Practice Teaches About Ethical Patient Engagement
India need not invent its answers from scratch. Over the past decade, mature systems have converged on a strikingly consistent set of principles for ethical patient engagement, and we can adapt rather than copy them. The European Federation of Pharmaceutical Industries and Associations (EFPIA) requires member companies to publicly disclose the support they give patient organisations and to respect those organisations’ independence. The Association of the British Pharmaceutical Industry (ABPI) expects written agreements, transparency, and autonomy. Medicines Australia, Innovative Medicines Canada, and the IFPMA have adopted comparable disclosure-first standards.
Regulators have moved in the same direction. The U.S. Food and Drug Administration’s Patient-Focused Drug Development initiative institutionalised the patient voice inside drug development itself. The European Medicines Agency now routinely seats patient representatives on scientific committees. Initiatives such as Patient Focused Medicines Development, the National Health Council, and disease-specific alliances like the Global Heart Hub have shown that structured patient engagement is not merely good ethics—it produces better clinical trials, better outcome measures, and better decisions.
The common thread is telling. Globally, the argument has already moved past whether patient organisations should participate to how they can participate while preserving independence. India’s health system, diversity, and access challenges are our own, so our model should be distinctly Indian while remaining globally credible. Notably, the strongest patient organisations abroad did not become trusted because regulation forced them to. They became trusted because they voluntarily adopted higher standards of disclosure and governance than any rule required. Trust, unlike regulation, cannot be mandated. It has to be earned.
The TRUST Framework for Ethical Patient Engagement
Healthcare does not need another checklist. It needs a shared philosophy simple enough to remember under pressure. I believe every partnership between industry and patient organisations should satisfy five principles of ethical patient engagement, which spell TRUST.
| Principle | What it demands | |
|---|---|---|
| T | Transparency | Funding sources, objectives, financial relationships, and conflicts of interest are disclosed by default, in language patients can actually understand. Trust grows when there is nothing to hide. |
| R | Respect for Independence | No editorial control, no approval rights, no censorship. A patient organisation must retain full authority over its educational content, policy positions, and advocacy. The ability to disagree respectfully is a sign of partnership maturity, not failure. |
| U | Unmet Need First | Every collaboration begins with one question—which patient problem are we solving?—not which campaign to fund, product to discuss, or event to sponsor. |
| S | Scientific Integrity | Benefits are explained; risks are explained with equal weight. Evidence is never selectively presented to serve a commercial narrative. This is the UCPMP’s balanced, verifiable, non-misleading standard applied to every patient-facing initiative. |
| T | Trust Through Governance | Aspiration becomes practice only through systems: independent boards, written agreements, conflict declarations, outcome evaluation, and external audit where appropriate. |
Five Questions to Ask Before Any Industry–Patient Partnership
Complex ethical frameworks are valuable, but simple ethical questions are the ones people actually remember. Before approving any collaboration, both a company and a patient organisation should be able to answer five of them honestly.
- Would we be comfortable if every detail of this partnership appeared on tomorrow’s front page?
- Would patients still trust this collaboration if they understood every financial arrangement in it?
- Would we publish the same report even if our sponsor disagreed with its conclusions?
- Can either party disagree, respectfully, without putting the relationship at risk?
- Are the patient outcomes clearly defined—and independently measurable?
If a partnership cannot survive those five questions, no amount of branding, budget, or good intentions will make it ethical.
Invest Beyond the Campaign: Fund Capability, Not Visibility
There is also a more constructive shift available to industry, and it may be the most important one. Healthcare has become extremely good at funding awareness campaigns—and far less interested in strengthening the institutions that must sustain awareness after the campaign ends. Imagine if a growing share of industry investment moved from short-lived visibility toward institutional capability: leadership development, governance systems, digital patient-education platforms, disease registries, peer-support infrastructure, translation into regional languages, patient-reported outcome measurement, and independent research capacity.
These investments rarely generate an immediate photograph. They generate something far more durable—institutional resilience. Strong institutions keep improving patient outcomes long after any single campaign has been forgotten. Funding a project builds an output. Funding capability builds an organisation. Only one of those still matters in five years. This is the same argument I have made about what pharma must see beyond the molecule.
Towards an Indian Charter for Ethical Patient Engagement
India stands at a genuine crossroads. Our pharmaceutical industry is globally significant, our medical-technology ecosystem is expanding fast, and our patient organisations are becoming more organised and more influential every year. The next step need not be another regulation imposed from above. It could instead be co-created governance—an Indian Charter for Ethical Patient Engagement, developed jointly by patient organisations, regulators, industry, healthcare professionals, and academia.
Such a charter would not replace existing law; the trusts, societies, Section 8 companies, tax rules, and foreign-contribution frameworks that already govern patient organisations would remain. It would instead strengthen the culture around them. At its heart could sit a short set of shared commitments: patients before products; transparency by default; editorial independence; scientific integrity; written partnership agreements; public disclosure of funding; respect for organisational autonomy; protection of patient data; diversity of funding sources wherever feasible; outcome-based evaluation; continuous public accountability; and an unwavering shared commitment to patient outcomes. None of these is revolutionary. Each simply reflects what patients already expect—and gives India the chance not merely to adopt global standards of ethical patient engagement, but to set the benchmark for the Global South.
The Innovation We Keep Overlooking: Learning to Trust
We speak endlessly about innovation—artificial intelligence, precision medicine, genomics, digital therapeutics, advanced diagnostics. Each is extraordinary. Yet healthcare’s most important innovation may turn out to be something far less glamorous: learning to trust one another well.
As a patient leader, I have worked alongside clinicians, researchers, regulators, governments, and industry across several countries. Despite our different vantage points, I have almost never found disagreement about the destination. Everyone wants patients to live longer, healthier, fuller lives. The difficulty has never been shared purpose. It has been designing systems in which different stakeholders can work together while preserving independence and public confidence.
Compliance is essential, but it only sets the floor. Trust asks more of us. It asks for transparency even when disclosure is uncomfortable, for independence even when agreement would be easier, and for measuring success not by the number of partnerships formed but by the number of lives improved because they existed. India can redefine what ethical collaboration looks like—not by building higher walls between stakeholders, but by building stronger bridges resting on transparency, accountability, and shared purpose.
Pharmaceutical companies bring scientific innovation. Medical-technology companies bring engineering ingenuity. Clinicians bring medical expertise. Governments bring policy and stewardship. Patient organisations bring the one thing no institution can manufacture: the lived reality of illness. When that voice remains independent, respected, and ethically engaged, everyone gains—patients receive better care, industry earns deeper trust, policymakers decide better, and clinicians see the outcomes that lie beyond the clinical endpoint.
The future of healthcare will not be determined only by the medicines we discover. It will be determined by the trust we choose to build.
Ethical patient engagement, in the end, is not a compliance exercise to be endured. It is one of the strongest investments any of us can make in a health system worth trusting. And perhaps that is the outcome that matters most of all.
Ethical Patient Engagement: Frequently Asked Questions
What is ethical patient engagement?
Ethical patient engagement is any collaboration between industry and patient organisations in which the patient organisation retains full independence over its content, advocacy positions and public statements, all financial relationships are disclosed by default, evidence is presented in a balanced way, and success is measured by patient outcomes rather than by activity. The test is simple: would the organisation publish the same report even if its sponsor disagreed?
Does UCPMP 2024 cover patient organisations in India?
Not directly. The Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 is built almost entirely around the relationship between a pharmaceutical company and healthcare professionals. Patient organisations are largely absent from its text. However, the Code’s underlying principles — balanced information, no misleading by implication, scientific integrity, transparency and accountability — apply logically to every patient-facing partnership. The silence is not permission, and ethical patient engagement in India must go beyond what the Code happens to prohibit.
Is it unethical for a patient organisation to accept pharmaceutical funding?
No. Funding itself is ethically neutral. What matters is dependency and influence. Support for evidence-based patient education, leadership development, disease registries, patient navigation or health-literacy programmes is legitimate. The line is crossed when money begins to shape scientific content, advocacy priorities or public positions.
What are the warning signs of an unhealthy industry–patient organisation partnership?
Six patterns recur: awareness campaigns that are really marketing; endorsement mistaken for engagement; ghost-written patient stories; single-sponsor capture; tokenism and conference tourism; and performative collaboration measured by MoUs signed rather than lives improved.
What is the TRUST framework?
TRUST is a five-part test for ethical patient engagement: Transparency, Respect for Independence, Unmet Need First, Scientific Integrity, and Trust Through Governance. It is designed to be simple enough to remember under pressure and specific enough to audit.
What would an Indian Charter for Ethical Patient Engagement contain?
A co-created charter would sit alongside existing law and set shared cultural commitments: patients before products; transparency by default; editorial independence; scientific integrity; written partnership agreements; public disclosure of funding; respect for organisational autonomy; protection of patient data; diversity of funding sources; outcome-based evaluation; and continuous public accountability.
Related Reading from Heart Health India Foundation
- India’s Chronic Disease Reality: What Pharma Must See Beyond the Molecule
- From Symptoms to Systems: Why Most Patients Enter Care Too Late
- Insights from the Global Cardiomyopathy Patient Council Meeting
- Why Cardiovascular Patients in India Need Social Prescribing
- HHIF Policy and Programme Advocacy
About the Author
Ram Khandelwal is a cardiac survivor and the Founder & CEO of Heart Health India Foundation, India’s first patient-led cardiovascular community. He works with clinicians, researchers, industry, and global patient organisations to advance patient-centred, ethically grounded healthcare—building resilient health systems in which lived experience is treated not only as a story worth hearing, but as evidence worth using.
Work with us: If you are a company, regulator, clinician or researcher who wants to build partnerships that meet this standard of ethical patient engagement, explore our policy and programme advocacy work or join the Heart Health India community.
